Key Points
- Harold Bernstein, Maze's CMO, sold 4,432 shares on Jan. 2 at $40.43 for $179,185.76 and has recently sold a total of 49,844 shares (including Dec. 29 and Jan. 5 trades) for roughly $2.02 million in proceeds.
- Maze Therapeutics (NASDAQ:MAZE) opened at $38.37, trades near its one‑year high ($43.29) with a market cap of $1.85 billion, and carries a generally positive Wall Street consensus (average "Buy" rating and average price target of $43.38).
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 412 shares of the company's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $40.00, for a total transaction of $16,480.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Harold Bernstein also recently made the following trade(s):
- On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total transaction of $179,185.76.
- On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00.
Maze Therapeutics Stock Down 0.7%
Shares of MAZE opened at $38.37 on Wednesday. The firm has a market cap of $1.85 billion and a PE ratio of -1.84. The company's fifty day moving average is $37.28 and its two-hundred day moving average is $25.45. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $43.29.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.08.
Analysts Set New Price Targets
MAZE has been the topic of several recent research reports. Guggenheim reiterated a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Friday, December 19th. Weiss Ratings restated a "sell (d)" rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Wedbush increased their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an "outperform" rating in a research report on Friday, November 7th. Lifesci Capital upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Thursday, December 18th. Finally, Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They issued an "overweight" rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $43.38.
Check Out Our Latest Stock Report on Maze Therapeutics
Institutional Trading of Maze Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. boosted its holdings in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after buying an additional 738 shares during the period. Legal & General Group Plc boosted its stake in Maze Therapeutics by 23.0% in the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company's stock worth $135,000 after purchasing an additional 977 shares during the period. Bank of America Corp DE grew its position in Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock worth $71,000 after purchasing an additional 1,455 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after purchasing an additional 1,725 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Maze Therapeutics in the third quarter valued at $52,000.
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
